WiseDiag

WiseDiag is a Chinese company specializing in AI-driven healthcare solutions, delivering innovative diagnostic tools and health management applications to enhance patient care and streamline clinical processes. Founded in 2023, WiseDiag operates from Hangzhou, China, focusing on developing advanced healthcare technologies. The company has secured Angel funding of CNY 65 million from investors including Lanshan Capital and Sinowisdom, and raised a total of CNY 65 million in its investment journey. The firm has completed one deal to date, with the most recent funding round occurring on May 6, 2026.

WiseDiag primarily offers advanced AI-driven healthcare solutions, including its flagship products: the WiseDiag medical multimodal model, the 好伴AI intelligent health management application, and the WiseClaw AI agent platform. The WiseDiag model utilizes deep learning and dual architecture for multi-modal diagnosis, supporting medical institutions with AI insights and treatment recommendations. The 好伴AI app acts as a personal health assistant, proactively identifying health risks and providing personalized lifestyle suggestions. The company serves over 300 hospitals and medical institutions across China, expanding its influence in telemedicine and health technology sectors.

WiseDiag generates revenue through B2B partnerships with healthcare institutions and direct-to-consumer subscriptions for its applications. Healthcare providers integrate the WiseDiag model into their systems via contracts that outline service agreements. The 好伴AI application is offered through subscription models, enabling users to access health management features and expert consultations. The company’s revenue streams benefit from strong relationships with key healthcare partners across public and private sectors in China.

With the recent Angel funding of CNY 65 million secured in May 2026, WiseDiag plans to enhance its capabilities in large-scale medical models and strengthen personal health management services. The company aims to promote the application of AI in healthcare, targeting new market expansions to further its reach. Specific details about upcoming product launches or geographic regions targeted for expansion have not been disclosed.